Buy Retatrutide: Triple Agonist Peptide for Research

Retatrutide (LY-3437943) is the first peptide to simultaneously activate three receptors: GLP-1, GIP and glucagon. This puts it a decisive step beyond semaglutide, which acts only on GLP-1, or tirzepatide, which combines GLP-1 and GIP. Anyone working at the forefront of metabolic peptide research can hardly ignore retatrutide.

Retatrutidemetabolic

First-ever triple-action weight management peptide targeting three receptors at once: GIP, GLP-1, and glucagon. Shown exceptional results in Phase 2 trials - up to 24% weight reduction. The most advanced metabolic peptide available.

What is Retatrutide?

Retatrutide is a synthetic peptide from Eli Lilly, currently in clinical trials. What makes it special: it is a so-called triple agonist - a single molecule that binds to three different receptors.

GLP-1 (Glucagon-like Peptide-1) controls insulin secretion and appetite regulation. This receptor is also activated by semaglutide and tirzepatide.

GIP (Glucose-dependent Insulinotropic Polypeptide) influences insulin sensitivity and fat metabolism. Tirzepatide also uses this pathway; semaglutide does not.

Glucagon increases energy expenditure, promotes lipolysis and drives thermogenesis. This third receptor is addressed only by retatrutide among the currently prominent peptides. That is its distinguishing feature.

Glucagon as the Key

Glucagon was long regarded as a pure antagonist of insulin. Current research paints a more nuanced picture: controlled glucagon receptor activation can increase energy expenditure and accelerate fat burning without compromising glycaemic control - provided GLP-1 and GIP are simultaneously active.

Research Data on Retatrutide

Clinical Trials

Phase 2 Results (NEJM, 2023)

338 participants, randomised, double-blind, placebo-controlled, over 48 weeks. Result of the highest dose group: mean weight reduction of approximately 24% of body weight. For comparison: semaglutide achieved approximately 15% in comparable studies, tirzepatide around 21%. The most common side effects were gastrointestinal in nature (nausea, diarrhoea, vomiting), similar to other GLP-1 agonists.

Phase 3 Results: TRIUMPH-4 (December 2025)

In December 2025, the first Phase 3 results were published: the TRIUMPH-4 study showed an average weight reduction of up to 32.3 kg (71.2 lbs). Additionally, WOMAC pain scores were reduced by up to 75.8%, and more than 1 in 8 patients was completely pain-free in the knee at the end of the study. Retatrutide also improved cardiovascular risk markers including non-HDL cholesterol and systolic blood pressure. The TRIUMPH programme includes over 5,800 participants in four Phase 3 studies - further results are expected in 2026.

Three Generations of GLP-1 Peptides

The development of GLP-1 peptides can roughly be divided into three generations. Semaglutide (Ozempic/Wegovy) as the first generation activates exclusively the GLP-1 receptor and achieved a weight reduction of approximately 15% in studies. Tirzepatide (Mounjaro/Zepbound) represents the second generation with a dual approach via GLP-1 and GIP, leading to around 21%. Retatrutide as the third generation combines all three receptors (GLP-1 + GIP + glucagon) and achieved the highest value so far with approximately 24%.

Further Research Directions

Weight research is only one aspect. Retatrutide is also being investigated in the context of MASLD and NASH, i.e. metabolic liver steatosis. Early data here show a significant reduction in liver fat content. Further studies address improvement of glycaemic control in type 2 diabetes, cardiovascular markers such as blood pressure and lipid profile, and exploratory investigations into sleep apnoea.

Why Buy Retatrutide at PeptidesDirect?

Janoshik-verified Quality

Every batch of retatrutide is tested independently by Janoshik Analytical. The Certificate of Analysis confirms identity by mass spectrometry, a purity of at least 98% by HPLC, the correct amino acid sequence and the absence of relevant impurities.

EU Shipping without Customs

PeptidesDirect ships from within the European Union. Intra-community delivery means: no import duties, no customs issues. Delivery time to most EU countries is two to three business days, with tracking and in discreet, neutral packaging.

Available Variants

Retatrutide is available at PeptidesDirect in multiple sizes, from small quantities for pilot experiments to batches for larger research series.

Retatrutidemetabolic

Retatrutide in Comparison

Compared to Tirzepatide

The approved drug tirzepatide (Mounjaro/Zepbound) activates two receptors, GLP-1 and GIP. Retatrutide adds the glucagon receptor. This third signalling pathway could increase energy expenditure more strongly than the dual approach alone. In studies to date, retatrutide has shown higher percentage weight reduction than tirzepatide.

Compared to Semaglutide

The approved drug semaglutide (Ozempic/Wegovy) is the best-known GLP-1 agonist and acts exclusively on GLP-1 receptors. Retatrutide has a broader spectrum of action. The advantage of semaglutide lies in its considerably longer clinical experience and existing approval. Retatrutide is still in Phase 3 studies.

Further GLP-1 Peptides

The research landscape is evolving rapidly.

Practical Research Notes

Reconstitution

Retatrutide is supplied as a lyophilised powder.

Storage

Before reconstitution, store at -20 °C in the freezer. Always protect from light and moisture. More detailed guidance is available in the Peptide Storage Guide.

Bacteriostatic Wateraccessories

USP-grade sterile water with 0.9% benzyl alcohol - the standard solvent for reconstituting lyophilized peptides. Essential accessory for any peptide research. Each vial is sealed and ready to use.

Frequently Asked Questions about Retatrutide

Conclusion

Retatrutide is the first triple agonist to unite GLP-1, GIP and glucagon in a single molecule. The clinical data to date clearly exceed the results of earlier GLP-1 agonists. For metabolic research, this opens new possibilities not achievable with mono- or dual agonists.

Retatrutidemetabolic